Cytophage in the news

Nutreco FeedTech Challenge - Cytophage

Cytophage Update on Upcoming Product for Egg Production in Canada

NEWS RELEASE​

Winnipeg, February 12, 2024 – Cytophage Technologies Ltd. (TSXV:CYTO) (“Cytophage” or the “Company”) is pleased to announced that it has completed research and development of its OvaPhage product…

Read More

Cytophage Technologies Ltd. Announces First Day of Trading

NEWS RELEASE​

Winnipeg, MB – February 7, 2024 – Cytophage Technologies Ltd. (“Cytophage” or the “Company”) (TSXV:CYTO) (formerly Cuspis Capital III Ltd. (“Cuspis”) (TSXV:CIII.P)) is pleased to announce…

Read More

Cytophage Technologies Ltd. Completes Reverse Takeover Transaction of Cuspis Capital III Ltd.

NEWS RELEASE​

TORONTO, CANADA, February 2, 2024 – Cytophage Technologies Ltd. (“Cytophage” or the “Resulting Issuer”) (formerly Cuspis Capital III Ltd. (“Cuspis”)) is pleased to announce the completion…

Read More

Cuspis Capital III Ltd. Announces Filing of Filing Statement with Respect to its Qualifying Transaction

NEWS RELEASE​

Toronto, Ontario – February 2, 2024 – Cuspis Capital III Ltd. (TSXV: CIII.P) (“Cuspis” or the “Corporation”), a capital pool company as defined under TSX Venture Exchange (“TSXV” or the “Exchange”) Policy 2.4 – Capital Pool Companies (“Policy 2.4”), is pleased to announce that…

Read More

This Winnipeg scientist is using viruses to fight drug-resistant superbugs

CBC News

Cutting-edge bacteriophage research has human and animal applications

Read More

Canadian Company Responding to Antibiotic Resistance Crisis through Innovation

News Release

In response to the recent outbreak of antibiotic-resistant salmonella affecting children across six provinces, inventive strategies are needed to address these types of emerging health crises. 

Read More

Cuspis Capital III Ltd. and Cytophage Technologies Inc. Announce Execution of Business Combination Agreement and Concurrent Financing

News Release

 Toronto – November 6, 2023 – Cuspis Capital III Ltd. (TSXV: CIII.P) (“Cuspis” or the “Corporation”), a capital pool company as defined under TSX Venture Exchange (“TSXV” or the “Exchange”) Policy 2.4 – Capital Pool Companies (“Policy 2.4”), and Cytophage Technologies Inc…

Read More

IN² Spotlight: How Phages Can Stop Drug-Resistant Bacteria

IN² - Innovation Incubator

A scientist co-discovered phages, viruses that only target bacteria, in 1915 and used them to treat cholera during a 1927 epidemic. The emergence of broad-spectrum antibiotics in the 1940s…

Read More

Cytophage Technologies Announces Distribution Agreement

News Release

Strategic partnership with leading animal health company in South Asia will expand market reach

Read More

Cytophage Technologies Expands Executive Team

News Release

Julius Kalcevich joins corporate leadership team as Chief Financial Officer; Michael Graham repositioned as Chief Commercial Officer

Read More

Cytophage Technologies Inc. Board of Directors Welcomes New Member and Board Advisor

News Release

Cytophage Technologies Inc., a Canadian biotech company that produces bacteriophages, is pleased to announce the appointment of Mr. Andy Hurley as Director to the Cytophage Technologies Inc. Board of Directors as of June 30, 2023. 

Read More

Cytophage Technologies Inc. Selected to Join the Wells Fargo Innovation Incubator Program​

News Release

Canadian biotech company Cytophage Technologies Inc. has been awarded $250,000 USD in non-dilutive funding to develop biological solutions for plant bacterial challenges at the Donald…

Read More

Winnipeg Biotech Company Tests New Ways of Fighting Common Swine Diseases

News Release

Manitoba biotech company Cytophage Technologies Inc. has been awarded $431,000 in government funding to help test a new way of fighting bacterial infections in swine without using antibiotics. 

Read More

Winnipeg Biotech Company Develops New Way to Catch and Kill COVID-19 Virus.

News Release

Award-winning Cytophage Technologies Inc. today announced it is about to begin animal testing on a throat and nasal spray that will stop infection by the SARS-CoV-2 virus and its variants…

Read More

Winnipeg-made antibiotic alternative attracting international attention.

News Release

Momentum is building this month at Winnipeg’s Cytophage Inc., as Dr. Steven Theriault, CEO, will be featured on the Interactive Investment forum — BioPub. It’s the fourth notable presentation of its kind this

Read More

Scientists are weaponizing viruses to solve a huge problem

Inverse.com

AS THE WORLD FIGHTS THE SARS-COV-2 VIRUS causing the COVID-19 pandemic, another group of dangerous pathogens looms in the background. The threat of antibiotic-resistant bacteria has been growing for years and appears to be getting worse.

Read More

Live Interview with Dr. Steven Theriault on The Tetrault Show

Canaccord Genuity Wealth Management / The Tetrault Show

Award Winning Virologist Shares Update On Scientific Advancement. With the abundance of information on Covid-19 at our disposal, it can sometime be overwhelming and difficult to separate fact from fiction.

Read More

Un chercheur crée des virus synthétiques pour vaincre les superbactéries

CBC Radio-Canada

Bactériophages. Ces virus naturels pourraient pourtant être à l’origine d’un nouveau traitement révolutionnaire contre les infections bactériennes résistantes aux antibiotiques, mis au point par un scientifique winnipégois.

Read More

How a Winnipeg entrepreneur is using Mother Nature's deadly weapon to fight antibiotic-resistant superbugs

FINANCIAL POST

One to watch: Steven Theriault’s research on bacteriophages has put him at the cutting edge of a potential bio-medical revolution

Read More

Antibiotic alternatives from Cytophage have big dairy applications

DAIRY REPORTER

Antimicrobial resistance in animals and humans could render antibiotics useless in the future. Cytophage pitched its solution for natural bacteriophage products at FoodBytes! this week.

Read More

Cytophage begins clinical trials, seeks partners to scale manufacturing capabilities

AGRIBUSINESS INTELLIGENCE

Originally focused on the human health sector, Cytophage Technologies has pivoted to animal health. As the company prepares clinical trials for its bacteriophage technology…

Read More

All the phage: Winnipeg company hopes to lead the fight against drug-resistant bacteria

GLOBAL NEWS

Before the discovery of penicillin almost a hundred years ago, doctors relied on other treatments to fight deadly infections. Now, after almost a century of overusing antibiotics, many infections…

Read More

Countless
Applications

Bacteriophage therapy has unlimited uses and is effective in eradicating bacterial disease and infection in three key areas.

Food Safety

In food safety, our phages help prevent disease and the spread of disease, without introducing antibiotics into the food chain or the environment.

Animal Health

Cytophage is developing bacteriophages that will reduce and ultimately replace the use of antibiotics for illness prevention and growth enhancement in livestock, starting with poultry.

Human Health

In human health, phages can address a full range of bacterial illnesses and conditions, from treating acne and eczema, alleviating internal bacterial infections such as pneumonia, preventing wound infections and battling outbreaks such as cholera or diphtheria.

Phages can also be used for the decontamination of hospital surfaces and counters, tools and instruments, beds and curtains, and anywhere else bacterial contamination is a concern.

What is a
bacteriophage?

Bacteriophages are organisms that infect and kill bacterial cells. These natural killers of bacteria can overcome all of the cellular or organism-level defences.

What is a
bacteriophage?

Bacteriophages are organisms that infect and kill bacterial cells. These natural killers of bacteria can overcome all of the cellular or organism-level defences.

We can win the war against battlefield infection.
Cytophage was selected for the Defense Innovation Award 2019.

Winner of 2018 Nutreco Feed Tech Challenge
For our breakthrough innovation to help feed the world.

Contact Us

Learn more about our bacteriophage solutions.

Cytophage Technologies Ltd. © 2019